News


  • 22 May 2014

    NovaMedica is recognized one of the best employers of Russia in 2013

    NovaMedica is recognized one of the best employers of Russia in 2013

    Russian pharmaceutical company “NovaMedica” won “Best Employer” prize as part of the National business award “Captains of the Russian Business”. The award winners are selected by the professional jury following the results of market experts’ opinion and companies’ activities survey over the past year.

  • 14 May 2014

    Regado Biosciences Announces First Quarter 2014 Financial Results and Corporate Highlights

    Regado Biosciences Announces First Quarter 2014 Financial Results and Corporate Highlights

    Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of the Revolixys™ Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced its first quarter 2014 corporate highlights and financial results. A conference call and webcast to discuss the results will be held, May 14, 2014, at 8:30 a.m. EDT.

  • 03 April 2014

    Evgeny Zaytsev, Managing Partner, RMI Partners: "It is great to witness young scientists grasping significant medical problems and addressing important global science trends"

    Evgeny Zaytsev, Managing Partner, RMI Partners: "It is great to witness young scientists grasping significant medical problems and addressing important global science trends"

    Two Russian biopharmaceutical projects teams, specializing in innovative medical technology developments, were awarded special prizes of RUSNANO development institutes as part of the Forum U-NOVUS and the contest of young scientists developments hosted in Tomsk.

     

  • 02 April 2014

    Regado Achieves 1,000-Patient Milestone in Phase 3 Trial of REG1

    Regado Achieves 1,000-Patient Milestone in Phase 3 Trial of REG1

    Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company leading the development of actively controllable therapeutics for acute care cardiovascular indications, today announced that after achieving the 1,000-patient enrollment milestone, enrollment in the REGULATE-PCI trial has been extended to non ST-elevated myocardial infarction (N-STEMI) patients to include the planned “all comers” percutaneous coronary intervention (PCI) patient population described in the trial protocol. 

  • 27 March 2014

    Syndax Files Registration Statement for Proposed Initial Public Offering

    Syndax Files Registration Statement for Proposed Initial Public Offering

    Syndax Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Syndax. The number of shares to be offered and the price range for the offering have not yet been determined.

  • 25 March 2014

    SIFI and NovaMedica sign agreement to market eight eye care products in Russia

    SIFI and NovaMedica sign agreement to market eight eye care products in Russia

    Leading Italian developer of innovative eye care solutions S.I.F.I. S.p.A. (SIFI) and Russian pharmaceutical company NovaMedica have entered into an exclusive commercial agreement  for NovaMedica to market eight products developed and licensed by SIFI for the treatment of a wide range of ophthalmic pathologies in Russia and the CIS.

  • 20 March 2014

    ECOG-ACRIN Opens Phase III Trial of SyndaxТs Entinostat in Advanced Breast Cancer

    ECOG-ACRIN Opens Phase III Trial of SyndaxТs Entinostat in Advanced Breast Cancer

    Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in its latest trial, E2112.

  • 19 March 2014

    FDA Designates Regado's REG1 in PCI as a Fast Track Development Program

    FDA Designates Regado's REG1 in PCI as a Fast Track Development Program

    Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration (FDA) has designated REG1 for anticoagulant therapy to be used in patients with coronary artery disease during percutaneous coronary interventions (PCI) as a Fast Track development program. The FDA's Fast Track process is designed to facilitate the development and expedite the review of drugs to treat serious conditions that fill an unmet medical need, with the overall goal of getting new drugs to patients earlier. 

  • 12 March 2014

    Regado Biosciences announces year-end 2013 financial results and corporate highlights

    Regado Biosciences announces year-end 2013 financial results and corporate highlights

    Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced its year-end 2013 corporate highlights and financial results. 

  • 13 February 2014

    Regado Biosciences, Inc., Announces FDA Acceptance of IND for REG2

    Regado Biosciences, Inc., Announces FDA Acceptance of IND for REG2

    Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration (FDA) has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.